Elsevier 2023 SDG mapping
Tips
How to read a Scopus query
The Scopus queries presented in this view correspond to what is known on scopus.com as advanced search queries. Advanced searches allow a query creator to create complex and robust queries using field codes, Boolean operators, or proximity operators. We detail each of these elements below.
Field codes
A typical publication's Scopus record contains a myriad of information about it. To make this information easily usable, this information is structured and parsed apart in different fields, each containing a given type of information. For example, the title field contains a publication's title, and the publication year field informs us about when a given publication was first made public.
Field codes are there to indicate which field(s) we would like to source information from when conducting a given search. To avoid searches becoming overly long, they are usually shortened words such as ABS, which stands for "Abstract". The most commonly-used field codes used by our query-building team are:
- TITLE-ABS-KEY
Searches through the Title, Abstract, and all Keywords - TITLE-ABS
Searches only through the Title and Abstract - AUTHKEY
Searches only through the Author-defined keywords - SRCTITLE
Searches only through the journal or conference proceedings' titles
To conduct a search in a given field, the syntax is always field-code(search-term).
The field codes used can potentially have a deep impact on a search. For example, searching for "Canada" in field AFFILCOUNTRY would return publications where at least one author was affiliated with a Canadian institution, while the same search conducted in field TITLE-ABS-KEY would return articles that concern Canada.
Boolean operators
In most cases, conducting a Scopus search using a single field code or a single term is not sufficient to obtain a robust set of results. To remedy this, Scopus searches make use of boolean operators to allow for the combination of different terms or query parts. The allowed operators are
- OR
At least one of the terms must appear in the specified field, or at least one of the searches must match - AND
Both of the terms must appear in the specified field, or both searches must match - AND NOT
Only the first term must appear in the specified field, or only the first search must match
Boolean operators are applied in the order they were listed above. Therefore, KEY(mouse AND NOT cat OR dog) is interpreted as KEY((mouse) AND NOT (cat OR dog)).
Proximity operators
In some instances, a certain word is deemed relevant to a topic only if it is close to another word in the text, or certain phrasings might space out two related words defining a topic, which we could want to be tolerant to. For example, the sentence "publishing scholarly journals" is relevant to the topic of "scholarly publishing", but searching for "scholarly publishing" alone would not capture an article that used this expression.
Using proximity searches enable building queries that are tolerant to such things. Two proximity search operators are available in Scopus:
- W/n
Both terms must be within n words of each other, but not in any particular order - PRE/n
Both terms must be within n words of each other, in the order they are listed in
For example, the search TITLE-ABS-KEY("journal" W/2 "publishing") would capture the sentence from the example above, but TITLE-ABS-KEY("journal" PRE/2 "publishing") would not, since the words are not in the same order.
Introduction
The United Nations Sustainable Development Goals (SDGs) challenge the global community to build a world where no one is left behind.
Since 2018, Elsevier has generated SDG search queries to help researchers and institutions track and demonstrate progress toward the SDG targets. In the past 3 years, these queries, along with the university’s own data and evidence supporting progress and contributions to the particular SDG outside of research-based metrics, are used for the THE Impact Rankings.
Method
For 2025, the SDGs use the exact same search query and ML algorithm as the Elsevier 2023 SDG mappings, with only minor modifications coming from changes to the search engine handling the SDG queries. Because of this, while the vast majority of publications retain their original mapping, the number of publications in each SDG has slightly changed.
All these changes were implemented to streamline how SDG queries are handled. Users should note that running these in Scopus should be done for reference purposes only, as the Scopus search engine behaves slightly differently than the classifier used to formerly tag SDGs to publications. Full details of the 2023 methodology are available on Digital Commons Data.
SDG 3 – Good Health and Well-being
Query
Below is the full search query used for SDG 3 – Good Health and Well-being. We’ve broken it down by each query component. Use the + and – buttons to expand or concatenate the different bracket levels.
Subfields of science
In this section, we show how the publication set, captured by the query above, relates to the Science-Metrix classification system.As shown in Figure 1, the publications related to this publication set fall mainly under the subfields of Oncology & Carcinogenesis (1,149,766 publications), Cardiovascular System & Hematology (565,033 publications) and General & Internal Medicine (521,748 publications). The total share of each subfield included under the publication set are presented upon hovering your cursor over the bars.
Journals
In this section, we show how the publication set, captured by the query above, relates to scholarly journals. Journals are sorted in terms of their total output in the field. The horizontal bars are proportional to the number of publications contributed by the journal to the current publication set. To see the proportion of the total publications in the journal contributing to this publication set or their relevance score, you can hover your cursor over the bars.The articles on this topic are published most frequently in the following journals: PLoS ONE (107,767 publications), Scientific Reports (56,313 publications) and International Journal of Molecular Sciences (41,321 publications).
Keywords
Elsevier’s Scopus database of scientific literature, was used for the table below. The document types included in the data sets are journal articles, reviews, short surveys and conference papers, covering the period 1996–2022. We refer to these documents collectively as “publications” or “papers”.In order to help better illustrate the content of this set of publications, indicators associated with the keywords most specific to this set (according to a TF-IDF score) are presented below.
Term | Papers with this term in the publication set | Papers with this term in all of Scopus | Relevance (tf-idf) | Percentage of Scopus |
---|---|---|---|---|
breast cancer resistance protein | 2421 | 2468 | 19.374382 | 98 |
international association for the study of lung cancer | 2272 | 2318 | 19.371101 | 98 |
national institutes of health stroke scale score | 1802 | 1820 | 19.370570 | 99 |
breast cancer resistance | 2657 | 2720 | 19.366095 | 98 |
functional assessment of cancer therapy | 2799 | 2864 | 19.365436 | 98 |
hodgkin lymphoma (hl) | 2399 | 2458 | 19.364585 | 98 |
sustained virological response (svr) | 2517 | 2585 | 19.360492 | 97 |
alcohol use disorders identification test | 2412 | 2481 | 19.357235 | 97 |
cancer theranostic | 2124 | 2180 | 19.356370 | 97 |
national cancer database | 3666 | 3725 | 19.354746 | 98 |
peripheral artery disease (pad) | 2853 | 2938 | 19.352216 | 97 |
adolescents with type 1 diabetes | 2581 | 2665 | 19.350068 | 97 |
kaposi's sarcoma-associated herpesvirus | 2112 | 2176 | 19.348812 | 97 |
european prospective investigation into cancer | 1621 | 1643 | 19.348381 | 99 |
stroke thrombectomy | 1713 | 1745 | 19.347822 | 98 |
sentinel lymph node biopsy (slnb) | 2171 | 2241 | 19.346913 | 97 |
shiga toxin-producing escherichia coli | 2601 | 2692 | 19.345442 | 97 |
hiv/hcv | 2134 | 2205 | 19.344056 | 97 |
anticancer therapeutic | 2891 | 2989 | 19.343834 | 97 |
pediatric obesity | 2438 | 2526 | 19.343555 | 97 |
oropharyngeal squamous cell carcinoma | 2573 | 2667 | 19.342717 | 96 |
childhood cancer survivors | 2520 | 2614 | 19.341443 | 96 |
substance-related disorder | 2287 | 2371 | 19.341008 | 96 |
cancer theranostics | 1766 | 1810 | 19.340842 | 98 |
marginal zone lymphoma | 2464 | 2558 | 19.339858 | 96 |
diabetes mellitus, type 2 | 1544 | 1565 | 19.339718 | 99 |
childhood cancer survivor | 2825 | 2929 | 19.339542 | 96 |
chemoradiotherapy (crt) | 2986 | 3093 | 19.338248 | 97 |
national institutes of health stroke scale (nihss) | 3228 | 3333 | 19.338158 | 97 |
metastatic colorectal cancer (mcrc) | 3183 | 3289 | 19.337997 | 97 |
chronic hepatitis c (chc) | 2524 | 2624 | 19.337170 | 96 |
substance-related disorders | 2128 | 2207 | 19.336888 | 96 |
biochemical failure | 2177 | 2260 | 19.336355 | 96 |
european organisation for research and treatment of cancer | 1840 | 1896 | 19.336049 | 97 |
metastatic renal cell carcinoma (mrcc) | 1804 | 1859 | 19.333571 | 97 |
distant metastasis-free survival | 2281 | 2374 | 19.333553 | 96 |
hiv-uninfected | 3309 | 3421 | 19.333167 | 97 |
mda-mb-231 breast cancer cells | 2056 | 2135 | 19.332227 | 96 |
barcelona clinic liver cancer | 1776 | 1830 | 19.331729 | 97 |
incident diabetes | 1998 | 2073 | 19.331564 | 96 |
stroke center | 2607 | 2718 | 19.331392 | 96 |
pandemic influenza a | 2107 | 2191 | 19.331307 | 96 |
mda-mb-231 breast cancer cell | 2627 | 2739 | 19.331149 | 96 |
slnb | 2765 | 2881 | 19.330906 | 96 |
international prognostic index | 2935 | 3054 | 19.330538 | 96 |
mcrpc | 2725 | 2841 | 19.330295 | 96 |
anaplastic lymphoma kinase (alk) | 3267 | 3385 | 19.330177 | 97 |
cancer-specific mortality | 3278 | 3396 | 19.330065 | 97 |
head and neck cancer (hnc) | 3106 | 3226 | 19.330055 | 96 |
substance use treatment | 2020 | 2100 | 19.328746 | 96 |
cancer drug delivery | 3496 | 3611 | 19.328634 | 97 |
her2 status | 2550 | 2663 | 19.328487 | 96 |
hcv treatment | 3122 | 3245 | 19.328195 | 96 |
disease-specific survival (dss) | 2759 | 2879 | 19.328140 | 96 |
prostate-specific membrane antigen (psma) | 2026 | 2108 | 19.327417 | 96 |
cancer and nutrition | 1569 | 1605 | 19.325939 | 98 |
androgen deprivation therapy (adt) | 3044 | 3171 | 19.325857 | 96 |
european prospective investigation into cancer and nutrition | 1441 | 1461 | 19.325474 | 99 |
adult congenital heart disease | 1883 | 1955 | 19.324643 | 96 |
anticancer drug delivery | 1711 | 1765 | 19.324552 | 97 |
adults with type 2 diabetes | 3263 | 3391 | 19.324427 | 96 |
metastatic crc | 1927 | 2004 | 19.323924 | 96 |
hcv genotype 1 | 2747 | 2873 | 19.323922 | 96 |
cryptogenic stroke | 1924 | 2001 | 19.323660 | 96 |
colorectal cancer (crc) screening | 1703 | 1757 | 19.323609 | 97 |
chronic hepatitis c virus (hcv) infection | 2606 | 2729 | 19.322917 | 95 |
european society for medical oncology | 3697 | 3816 | 19.322373 | 97 |
neoadjuvant chemoradiation | 2076 | 2168 | 19.322313 | 96 |
hiv-1 subtype | 3244 | 3376 | 19.322254 | 96 |
cancer targeted | 2504 | 2624 | 19.321993 | 95 |
pdm09 | 2301 | 2410 | 19.321861 | 95 |
metastatic castration-resistant prostate cancer (mcrpc) | 1637 | 1685 | 19.321790 | 97 |
national institute of health stroke scale | 1832 | 1902 | 19.321620 | 96 |
anticancer efficacy | 3187 | 3321 | 19.321403 | 96 |
pathologic complete response (pcr) | 1648 | 1698 | 19.321051 | 97 |
substance use disorder (sud) | 2297 | 2407 | 19.320873 | 95 |
high-risk prostate cancer | 1862 | 1936 | 19.320736 | 96 |
nsclcs | 2228 | 2334 | 19.320346 | 95 |
follicular lymphoma (fl) | 2183 | 2286 | 19.320128 | 95 |
asthma phenotype | 1734 | 1795 | 19.319996 | 97 |
hbv genotype | 2167 | 2269 | 19.319958 | 96 |
diabetes status | 2919 | 3055 | 19.319631 | 96 |
non–small cell lung | 1979 | 2066 | 19.319222 | 96 |
metastatic breast cancer (mbc) | 2622 | 2751 | 19.319141 | 95 |
plasma hiv-1 rna | 1438 | 1463 | 19.318798 | 98 |
shiga toxin-producing escherichia coli (stec) | 1645 | 1697 | 19.318504 | 97 |
hcc recurrence | 1904 | 1985 | 19.318112 | 96 |
cvd events | 3166 | 3306 | 19.317932 | 96 |
castration-resistant prostate cancer (crpc) | 2487 | 2612 | 19.317748 | 95 |
global initiative for chronic obstructive lung disease | 1706 | 1766 | 19.317709 | 97 |
health services accessibility | 1928 | 2012 | 19.317526 | 96 |
pandemic h1n1 | 1810 | 1882 | 19.317385 | 96 |
anticancer therapeutics | 1635 | 1687 | 19.317185 | 97 |
non-muscle-invasive | 1842 | 1918 | 19.316818 | 96 |
2009 pandemic | 2024 | 2118 | 19.316642 | 96 |
non–small cell | 2001 | 2093 | 19.316557 | 96 |
suicide gene | 2512 | 2640 | 19.316462 | 95 |
targeted cancer therapy | 2164 | 2270 | 19.316448 | 95 |
escherichia coli (stec) | 2363 | 2483 | 19.316333 | 95 |
sustained virologic response | 3715 | 3845 | 19.316270 | 97 |
asthma control test | 1754 | 1821 | 19.316189 | 96 |
effusion lymphoma | 1518 | 1556 | 19.316137 | 98 |
mantle cell lymphoma (mcl) | 2363 | 2484 | 19.315568 | 95 |
direct-acting antivirals | 3209 | 3353 | 19.315453 | 96 |
combination antiretroviral therapy (cart) | 1845 | 1923 | 19.315195 | 96 |
cancer-related fatigue | 1732 | 1798 | 19.314638 | 96 |
anthracycline-based | 2111 | 2215 | 19.314530 | 95 |
risk of ischemic stroke | 2549 | 2682 | 19.314135 | 95 |
sentinel node biopsy | 3291 | 3437 | 19.313880 | 96 |
metastatic rcc | 2212 | 2325 | 19.313727 | 95 |
interferon and ribavirin | 2763 | 2905 | 19.313537 | 95 |
tumor-node-metastasis | 2416 | 2543 | 19.313429 | 95 |
adjuvant chemoradiation | 2876 | 3021 | 19.313416 | 95 |
crc risk | 2180 | 2291 | 19.313352 | 95 |
sln biopsy | 1478 | 1513 | 19.313308 | 98 |
national comprehensive cancer network | 3885 | 4013 | 19.313168 | 97 |
concurrent chemoradiation | 2124 | 2231 | 19.312912 | 95 |
pharyngeal squamous cell carcinoma | 3352 | 3499 | 19.312846 | 96 |
neoadjuvant chemotherapy (nac) | 3010 | 3158 | 19.312820 | 95 |
epidermal growth factor receptor (egfr) mutation | 2141 | 2250 | 19.312415 | 95 |
non–small cell lung cancer | 1873 | 1957 | 19.312292 | 96 |
sentinel lymph node (sln) | 3137 | 3287 | 19.312034 | 95 |
metastatic castration-resistant prostate cancer | 3257 | 3407 | 19.311779 | 96 |
end-stage kidney disease (eskd) | 1595 | 1647 | 19.311668 | 97 |
acute ischemic stroke patients | 2769 | 2914 | 19.311666 | 95 |
hiv/sti | 1518 | 1560 | 19.311475 | 97 |
cancer cell apoptosis | 2422 | 2552 | 19.311448 | 95 |
chronic thromboembolic pulmonary hypertension | 2552 | 2689 | 19.311386 | 95 |
prostate cancer (pc) | 3327 | 3477 | 19.311357 | 96 |
atherosclerosis cardiovascular disease | 2750 | 2895 | 19.311278 | 95 |
autoimmune hepatitis (aih) | 2337 | 2462 | 19.311225 | 95 |
egfr tyrosine kinase inhibitors | 1929 | 2020 | 19.311156 | 95 |
metastatic setting | 2038 | 2140 | 19.310732 | 95 |
advanced hepatocellular carcinoma (hcc) | 1785 | 1861 | 19.310699 | 96 |
hiv prevention intervention | 1827 | 1908 | 19.310410 | 96 |
prevention of mother-to-child transmission | 2001 | 2100 | 19.310320 | 95 |
prostate cancer treatment | 2984 | 3136 | 19.310159 | 95 |
primary effusion lymphoma | 1476 | 1514 | 19.309388 | 97 |
hiv-infected adults | 2746 | 2894 | 19.309194 | 95 |
obesity type | 2341 | 2469 | 19.309120 | 95 |
chronic hepatitis c virus (hcv) | 3406 | 3559 | 19.309000 | 96 |
primary effusion | 1502 | 1544 | 19.308921 | 97 |
crc screening | 3222 | 3378 | 19.308436 | 95 |
locally advanced rectal cancer | 3471 | 3624 | 19.308289 | 96 |
large vessel occlusion | 2952 | 3107 | 19.307989 | 95 |
papillary thyroid cancer (ptc) | 2025 | 2129 | 19.307916 | 95 |
latent tuberculosis infection | 3195 | 3352 | 19.307898 | 95 |
chronic thromboembolic pulmonary | 2570 | 2713 | 19.307744 | 95 |
hbv dna level | 2411 | 2546 | 19.307220 | 95 |
metastatic castration-resistant | 3428 | 3584 | 19.307126 | 96 |
diabetes medication | 2091 | 2202 | 19.307109 | 95 |
nmibc | 2289 | 2416 | 19.307094 | 95 |
ckd stages | 2194 | 2314 | 19.306895 | 95 |
cancer stem cell (csc) | 1936 | 2033 | 19.306301 | 95 |
substance use disorders (suds) | 1680 | 1748 | 19.306063 | 96 |
neuroblastoma sh-sy5y cell | 1829 | 1915 | 19.305785 | 96 |
cancer-related genes | 2552 | 2697 | 19.305700 | 95 |
diabetes self-management | 3198 | 3359 | 19.305564 | 95 |
msi-h | 2353 | 2487 | 19.305142 | 95 |
cancer cell survival | 2685 | 2837 | 19.305015 | 95 |
neuroblastoma sh-sy5y | 2011 | 2117 | 19.304971 | 95 |
prostate cancer progression | 3156 | 3318 | 19.304956 | 95 |
obesity and metabolic syndrome | 2148 | 2267 | 19.304575 | 95 |
women living with hiv | 2401 | 2539 | 19.304505 | 95 |
prevalence of type 2 diabetes | 2495 | 2639 | 19.304239 | 95 |
and end results database | 2320 | 2453 | 19.304152 | 95 |
hiv acquisition | 2362 | 2498 | 19.304081 | 95 |
peritoneal cancer | 2029 | 2138 | 19.303867 | 95 |
a549 lung cancer | 1794 | 1878 | 19.303820 | 96 |
men living with hiv | 2959 | 3121 | 19.303702 | 95 |
cancer stem-like | 2354 | 2490 | 19.303668 | 95 |
brca mutation | 2737 | 2893 | 19.303658 | 95 |
exposure to pm2.5 | 2057 | 2169 | 19.303577 | 95 |
prostate cancer diagnosis | 1897 | 1993 | 19.303419 | 95 |
sentinel nodes | 2055 | 2167 | 19.303415 | 95 |
anti-cancer properties | 2097 | 2213 | 19.303318 | 95 |
brca2 mutation | 3019 | 3183 | 19.303070 | 95 |
cancer survivorship | 3506 | 3668 | 19.302998 | 96 |
progression of chronic kidney disease | 1829 | 1918 | 19.302887 | 95 |
transarterial chemoembolization (tace) | 2426 | 2568 | 19.302703 | 94 |
uncontrolled asthma | 1899 | 1996 | 19.302689 | 95 |
egfr tk | 1767 | 1849 | 19.302639 | 96 |
differentiated thyroid cancer (dtc) | 1701 | 1775 | 19.302550 | 96 |
american joint committee on cancer (ajcc) | 2139 | 2260 | 19.302265 | 95 |
alcohol use disorder (aud) | 2895 | 3058 | 19.302216 | 95 |
children with type 1 diabetes | 2634 | 2788 | 19.302162 | 94 |
egfr-tkis | 2460 | 2605 | 19.302031 | 94 |
visceral obesity | 2719 | 2877 | 19.301873 | 95 |
hormone receptor-positive | 3102 | 3269 | 19.301818 | 95 |
chb patients | 2871 | 3035 | 19.301192 | 95 |
cancer stem-like cell | 2100 | 2219 | 19.301009 | 95 |
end results database | 2346 | 2485 | 19.300955 | 94 |
opscc | 1475 | 1520 | 19.300864 | 97 |
obesity rates | 2258 | 2391 | 19.300536 | 94 |
ca-mrsa | 1860 | 1955 | 19.300515 | 95 |
brca1/2 mutation | 2147 | 2271 | 19.300357 | 95 |
obstructive cad | 1556 | 1613 | 19.300243 | 96 |
tki therapy | 1629 | 1696 | 19.300132 | 96 |
type 2 diabetes mellitus (dm) | 2652 | 2810 | 19.299976 | 94 |
trail-induced apoptosis | 1775 | 1861 | 19.299617 | 95 |
international diabetes federation | 2850 | 3016 | 19.299538 | 94 |
stroke therapy | 2267 | 2402 | 19.299513 | 94 |
persons living with hiv | 2305 | 2443 | 19.299435 | 94 |
her2 expression | 2080 | 2199 | 19.299429 | 95 |
pm2.5 exposure | 2915 | 3083 | 19.299364 | 95 |
allergy, asthma | 4632 | 4736 | 19.298914 | 98 |
cvd event | 3654 | 3820 | 19.298805 | 96 |
folfiri | 2964 | 3134 | 19.298795 | 95 |
atherosclerotic cardiovascular disease (ascvd) | 1998 | 2110 | 19.298522 | 95 |
human prostate cancer cells | 2932 | 3102 | 19.298361 | 95 |
l858r | 2313 | 2453 | 19.298349 | 94 |
inflammation and cancer | 2408 | 2555 | 19.298123 | 94 |
adult congenital heart | 1964 | 2073 | 19.298058 | 95 |
improving global outcomes | 2105 | 2228 | 19.298021 | 94 |
tyrosine kinase inhibitor (tki) | 3069 | 3242 | 19.298019 | 95 |
weekly paclitaxel | 1584 | 1647 | 19.297857 | 96 |
recurrent ovarian cancer | 2029 | 2145 | 19.297752 | 95 |
egfr tki | 1653 | 1726 | 19.297116 | 96 |
cancer stem-like cells | 1890 | 1992 | 19.297106 | 95 |
survivorship care | 1736 | 1820 | 19.296811 | 95 |
metastatic nsclc | 1912 | 2017 | 19.296595 | 95 |
cancer mechanism | 2830 | 3000 | 19.296572 | 94 |
ventilator-associated pneumonia (vap) | 2980 | 3154 | 19.296524 | 94 |
chronic thromboembolic pulmonary hypertension (cteph) | 1552 | 1612 | 19.296225 | 96 |
her2-negative | 3179 | 3356 | 19.296220 | 95 |
her2-positive breast cancer | 2912 | 3085 | 19.296174 | 94 |
pathologic complete response | 3348 | 3525 | 19.296085 | 95 |
cardiovascular disease (cvd) risk | 4003 | 4160 | 19.295944 | 96 |
nonsmall cell lung cancer | 2959 | 3134 | 19.295630 | 94 |
asthma outcome | 1479 | 1529 | 19.295618 | 97 |
stroke subtype | 2993 | 3169 | 19.295454 | 94 |
baseline hba1c | 1663 | 1739 | 19.295344 | 96 |
endometrial cancer (ec) | 2481 | 2637 | 19.294957 | 94 |
h5n1 virus | 2332 | 2478 | 19.294826 | 94 |
health services access | 2127 | 2256 | 19.294703 | 94 |
type 1 diabetes mellitus (t1dm) | 4087 | 4242 | 19.294664 | 96 |
significant prostate cancer | 1679 | 1758 | 19.294414 | 96 |
tuberculin skin test (tst) | 1797 | 1891 | 19.294366 | 95 |
milan criteria | 1619 | 1690 | 19.294357 | 96 |
neuroblastoma sh-sy5y cells | 1604 | 1673 | 19.294291 | 96 |
breast cancer mcf-7 | 2197 | 2333 | 19.294114 | 94 |
substance use problem | 1610 | 1680 | 19.294103 | 96 |
cancer epigenetic | 1844 | 1944 | 19.294007 | 95 |
stroke outcomes | 1646 | 1721 | 19.293997 | 96 |
diabetic kidney disease (dkd) | 2006 | 2124 | 19.293953 | 94 |
new-onset diabetes | 2045 | 2167 | 19.293933 | 94 |
tki treatment | 1690 | 1771 | 19.293838 | 95 |
cancer inflammation | 1752 | 1841 | 19.293803 | 95 |
child obesity | 1607 | 1677 | 19.293652 | 96 |
cancer-related gene | 2996 | 3175 | 19.293652 | 94 |
peg-ifn | 2613 | 2779 | 19.293185 | 94 |
hnscc patients | 2457 | 2614 | 19.293125 | 94 |
sustained virologic response (svr) | 1497 | 1552 | 19.292855 | 96 |
targeting cancer | 2515 | 2676 | 19.292853 | 94 |
integrase inhibitor | 2434 | 2590 | 19.292747 | 94 |
overweight, obesity | 1805 | 1902 | 19.292393 | 95 |
muscle invasive bladder cancer | 2688 | 2859 | 19.292269 | 94 |
ln metastasis | 2706 | 2878 | 19.292144 | 94 |
oligometastatic | 2309 | 2457 | 19.291937 | 94 |
stroke thrombolysis | 1491 | 1546 | 19.291817 | 96 |
surveillance, epidemiology, and end results database | 1752 | 1843 | 19.291802 | 95 |
anti-obesity effect | 2109 | 2240 | 19.291614 | 94 |
colorectal cancer risk | 2801 | 2978 | 19.291398 | 94 |
clear cell rcc | 1756 | 1848 | 19.291311 | 95 |
t790m | 2821 | 2999 | 19.291220 | 94 |
egfr tyrosine kinase inhibitor | 3107 | 3292 | 19.291145 | 94 |
hcc development | 2926 | 3108 | 19.290769 | 94 |
advanced hcc | 3375 | 3562 | 19.290426 | 95 |
hiv coinfection | 1607 | 1680 | 19.290388 | 96 |
cancer cell death | 3816 | 3994 | 19.289860 | 96 |
stroke registry | 2008 | 2131 | 19.289746 | 94 |
substance use problems | 1504 | 1563 | 19.289404 | 96 |
incidence of type 2 diabetes | 1732 | 1823 | 19.289219 | 95 |
controlled asthma | 3349 | 3539 | 19.288848 | 95 |
kaposi's sarcoma-associated herpesvirus (kshv) | 1333 | 1366 | 19.288690 | 98 |
persistent asthma | 3711 | 3895 | 19.288653 | 95 |
chronic thromboembolic | 2841 | 3024 | 19.288463 | 94 |
genotype 1b | 2162 | 2302 | 19.288305 | 94 |
neoadjuvant chemoradiotherapy | 3376 | 3567 | 19.288215 | 95 |
a549 lung cancer cell | 1606 | 1681 | 19.288061 | 96 |
prostate-specific membrane | 3075 | 3265 | 19.287889 | 94 |
anticancer mechanism | 1576 | 1647 | 19.287753 | 96 |
prostate-specific membrane antigen | 3060 | 3250 | 19.287732 | 94 |
lymph node ratio | 1555 | 1623 | 19.287706 | 96 |
breast cancer model | 2608 | 2782 | 19.287483 | 94 |
2009 h1n1 | 1786 | 1886 | 19.287162 | 95 |
programmed death-ligand 1 (pd-l1) | 2065 | 2197 | 19.287086 | 94 |
merkel cell carcinoma (mcc) | 1551 | 1619 | 19.287050 | 96 |
tumor necrosis factor-related apoptosis-inducing ligand | 2490 | 2658 | 19.286717 | 94 |
obesity rate | 2717 | 2898 | 19.286476 | 94 |
brca1 or brca2 | 1674 | 1760 | 19.286414 | 95 |
hallmarks of cancer | 2616 | 2792 | 19.286408 | 94 |
pmtct | 2076 | 2210 | 19.286337 | 94 |
diabetes-related complication | 1717 | 1809 | 19.286206 | 95 |
breast cancer subtypes | 2727 | 2909 | 19.286118 | 94 |
pathological complete response (pcr) | 1900 | 2015 | 19.286115 | 94 |
drug use disorder | 1478 | 1536 | 19.285988 | 96 |
stroke subtypes | 1907 | 2023 | 19.285948 | 94 |
latent tuberculosis infection (ltbi) | 1537 | 1604 | 19.285850 | 96 |
cancer-specific survival (css) | 3171 | 3366 | 19.285714 | 94 |
b-cell non-hodgkin lymphoma | 1556 | 1626 | 19.285629 | 96 |
flt3-itd | 1876 | 1989 | 19.285333 | 94 |
antiretroviral treatment (art) | 2185 | 2331 | 19.285161 | 94 |
diffuse large b cell lymphoma | 3246 | 3443 | 19.284898 | 94 |
a(h1n1)pdm09 | 1389 | 1434 | 19.284860 | 97 |
asthma outcomes | 1321 | 1355 | 19.284795 | 97 |
resistant breast cancer | 2190 | 2337 | 19.284726 | 94 |
combination antiretroviral therapy | 3925 | 4109 | 19.284724 | 96 |
adults with diabetes | 2894 | 3085 | 19.284534 | 94 |
anticancer therapies | 3679 | 3872 | 19.284520 | 95 |
human colorectal cancer cell | 2217 | 2367 | 19.284297 | 94 |
people living with hiv (plwh) | 2184 | 2331 | 19.284277 | 94 |
asthma and copd | 2425 | 2592 | 19.284201 | 94 |
eastern cooperative oncology group performance status | 3208 | 3406 | 19.284181 | 94 |
cancer history | 2109 | 2249 | 19.284084 | 94 |
alk-positive | 1694 | 1785 | 19.284062 | 95 |
hiv-exposed | 1769 | 1870 | 19.284038 | 95 |
chronic thromboemboli | 2893 | 3085 | 19.283885 | 94 |
cteph | 1803 | 1909 | 19.283421 | 94 |
lung cancer treatment | 2660 | 2843 | 19.283247 | 94 |
ckd progression | 1940 | 2063 | 19.283060 | 94 |
nucleos(t)ide analog | 1800 | 1906 | 19.283050 | 94 |
chronic hepatitis c patients | 2255 | 2410 | 19.283013 | 94 |
mucosa-associated lymphoid tissue lymphoma | 1578 | 1654 | 19.282551 | 95 |
hiv-1 integrase | 1827 | 1937 | 19.282491 | 94 |
hiv-rna | 1452 | 1509 | 19.282392 | 96 |
hiv stigma | 1439 | 1494 | 19.282337 | 96 |
hcv therapy | 1376 | 1421 | 19.282218 | 97 |
crc cell lines | 2455 | 2627 | 19.282113 | 93 |
hiv-associated neurocognitive disorder | 1527 | 1596 | 19.281877 | 96 |
asthma model | 2043 | 2179 | 19.281693 | 94 |
hcc treatment | 1975 | 2104 | 19.281270 | 94 |
cancer development and progression | 3617 | 3818 | 19.281146 | 95 |
h5n1 influenza | 1502 | 1568 | 19.280942 | 96 |
upper tract urothelial carcinoma | 1476 | 1538 | 19.280911 | 96 |
acute ischemic stroke (ais) | 3823 | 4019 | 19.280793 | 95 |
her2 positive | 1834 | 1947 | 19.280471 | 94 |
cancer thyroid | 2165 | 2315 | 19.280381 | 94 |
cancer diagnoses | 3222 | 3427 | 19.280240 | 94 |
cancer gene therapy | 3368 | 3574 | 19.279972 | 94 |
national cancer data base | 1269 | 1298 | 19.279764 | 98 |
stroke recurrence | 2147 | 2296 | 19.279761 | 94 |
nucleos(t)ide | 2147 | 2296 | 19.279761 | 94 |
diabetes model | 1773 | 1879 | 19.279632 | 94 |
diabetes-related complications | 1642 | 1730 | 19.279613 | 95 |
thromboembolic pulmonary hypertension | 2611 | 2797 | 19.279348 | 93 |
resistant cancer cells | 2036 | 2174 | 19.279324 | 94 |
tumor-associated macrophages (tams) | 2577 | 2761 | 19.279318 | 93 |
cancer cell cycle | 2160 | 2311 | 19.279171 | 93 |
epithelial ovarian cancer (eoc) | 3552 | 3758 | 19.279137 | 95 |
recovery after stroke | 1708 | 1806 | 19.278862 | 95 |
hepatitis e virus (hev) | 3525 | 3732 | 19.278808 | 94 |
cancer detection rate | 2184 | 2338 | 19.278626 | 93 |
cancer xenograft model | 1401 | 1453 | 19.278548 | 96 |
obesity risk | 3817 | 4018 | 19.278418 | 95 |
second-line chemotherapy | 2620 | 2808 | 19.278340 | 93 |
breast cancer stem cell | 1903 | 2027 | 19.278168 | 94 |
and type 1 diabetes | 2050 | 2191 | 19.278054 | 94 |
response evaluation criteria in solid tumors | 3810 | 4012 | 19.278037 | 95 |
brca1 mutation | 2156 | 2308 | 19.278035 | 93 |
muscle-invasive bladder cancer | 4023 | 4217 | 19.277804 | 95 |
hereditary breast | 3387 | 3597 | 19.277756 | 94 |
pancreatic cancer cell lines | 2794 | 2992 | 19.277627 | 93 |
asthma diagnosis | 1742 | 1846 | 19.277505 | 94 |
nonsmall cell lung cancer (nsclc) | 1470 | 1534 | 19.277443 | 96 |
diffuse large b cell | 3498 | 3708 | 19.277381 | 94 |
obesity status | 1778 | 1887 | 19.277340 | 94 |
ischemic stroke (is) | 2444 | 2622 | 19.277177 | 93 |
chronic hepatitis b patients | 2590 | 2778 | 19.277104 | 93 |
insulin resistance obesity | 2776 | 2974 | 19.277102 | 93 |
treatment of hepatitis c | 2057 | 2200 | 19.276994 | 94 |
adults with congenital heart disease | 1537 | 1612 | 19.276804 | 95 |
hbv dna levels | 1693 | 1791 | 19.276729 | 95 |
nab-paclitaxel | 1929 | 2058 | 19.276470 | 94 |
gastric cancer cell lines | 2639 | 2831 | 19.276368 | 93 |
her2 overexpression | 1432 | 1491 | 19.276144 | 96 |
incident stroke | 1363 | 1411 | 19.275691 | 97 |
tumor necrosis factor-related apoptosis-inducing ligand (trail) | 1803 | 1917 | 19.275691 | 94 |
hcv patients | 3376 | 3590 | 19.275575 | 94 |
hiv viral load | 3451 | 3665 | 19.275445 | 94 |
disease control rate (dcr) | 2124 | 2276 | 19.275384 | 93 |
breast cancer susceptibility | 2630 | 2823 | 19.275332 | 93 |
adults with cancer | 1785 | 1897 | 19.275321 | 94 |
brca2 mutations | 1690 | 1789 | 19.275270 | 94 |
metabolic tumor volume | 1567 | 1648 | 19.275219 | 95 |
testis antigen | 1654 | 1748 | 19.275113 | 95 |
nonsmall cell lung | 3447 | 3662 | 19.274919 | 94 |
apoptosis of cancer cells | 1431 | 1491 | 19.274737 | 96 |
cannabis use disorder | 1449 | 1512 | 19.274641 | 96 |
stroke recovery | 2385 | 2562 | 19.274564 | 93 |
mpmri | 1887 | 2013 | 19.274520 | 94 |
breast cancer mcf-7 cell | 1650 | 1744 | 19.274504 | 95 |
virologic failure | 1642 | 1735 | 19.274330 | 95 |
targeted anticancer | 1516 | 1590 | 19.274245 | 95 |
hiv co-infection | 2148 | 2304 | 19.274117 | 93 |
multidrug-resistant tuberculosis (mdr-tb) | 1487 | 1557 | 19.273577 | 96 |
prostate cancer detection | 1952 | 2087 | 19.273552 | 94 |
cancer initiation and progression | 1816 | 1934 | 19.273491 | 94 |
transcatheter arterial chemoembolization (tace) | 1877 | 2003 | 19.273360 | 94 |
response evaluation criteria in solid tumor | 3943 | 4150 | 19.273249 | 95 |
b-cell lymphoma-2 | 1674 | 1773 | 19.272914 | 94 |
drug-resistant tb | 2344 | 2520 | 19.272775 | 93 |
stroke severity | 4247 | 4440 | 19.272753 | 96 |
type 2 diabetes (t2dm) | 4104 | 4305 | 19.272671 | 95 |
diabetes prevention | 4028 | 4233 | 19.272489 | 95 |
invasive coronary angiography | 2305 | 2478 | 19.272483 | 93 |
breast and prostate cancer | 2547 | 2739 | 19.272400 | 93 |
obesity and insulin resistance | 3673 | 3890 | 19.272330 | 94 |
prostate cancer risk | 3887 | 4098 | 19.272330 | 95 |
recurrent prostate cancer | 1480 | 1550 | 19.272271 | 95 |
objective response rate (orr) | 3629 | 3847 | 19.272246 | 94 |
anti-cancer effects | 3767 | 3982 | 19.272209 | 95 |
diabetes technology | 1704 | 1808 | 19.272190 | 94 |
highly pathogenic avian influenza | 3575 | 3794 | 19.272160 | 94 |
large b cell lymphoma | 3582 | 3801 | 19.272110 | 94 |
lung cancer surgery | 1906 | 2037 | 19.272102 | 94 |
hepatitis c virus genotype | 1896 | 2026 | 19.271875 | 94 |
hepatitis c (hcv) | 2200 | 2364 | 19.271854 | 93 |
cancer diagnosis and treatment | 2609 | 2806 | 19.271734 | 93 |
tnbc cells | 2370 | 2550 | 19.271419 | 93 |
breast cancer resistance protein (bcrp) | 1201 | 1224 | 19.271386 | 98 |
large b-cell lymphomas | 1525 | 1603 | 19.271303 | 95 |
pca cells | 2563 | 2758 | 19.271060 | 93 |
plasma hiv rna | 1284 | 1322 | 19.271051 | 97 |
curative-intent | 1710 | 1816 | 19.271026 | 94 |
protumor | 1872 | 2000 | 19.270916 | 94 |
cancer-related mortality | 3539 | 3761 | 19.270814 | 94 |
asthma exacerbations | 4165 | 4367 | 19.270753 | 95 |
braf mutations | 2646 | 2847 | 19.270559 | 93 |
hiv-1 subtypes | 1404 | 1463 | 19.270513 | 96 |
clinically localized prostate cancer | 2134 | 2293 | 19.270480 | 93 |
european organization for research and treatment of cancer | 3853 | 4069 | 19.270452 | 95 |
b-cell lymphoma 2 | 2710 | 2915 | 19.270343 | 93 |
cardiovascular disease (cvd) risk factors | 1415 | 1476 | 19.270314 | 96 |
cancer pathogenesis | 3252 | 3475 | 19.270197 | 94 |
high-grade serous | 3181 | 3403 | 19.270196 | 93 |
sh-sy5y neuroblastoma | 1889 | 2020 | 19.270147 | 94 |
environmental and human health | 2130 | 2289 | 19.270135 | 93 |
cancer diagnostics | 3002 | 3220 | 19.270030 | 93 |
bladder cancer (bc) | 1943 | 2081 | 19.269898 | 93 |
cancer resistance | 4218 | 4419 | 19.269884 | 95 |
advanced non-small cell lung cancer (nsclc) | 3634 | 3857 | 19.269632 | 94 |
chemoradiation therapy | 3429 | 3654 | 19.269568 | 94 |
nsclc cell lines | 2704 | 2910 | 19.269463 | 93 |
circulating tumor dna (ctdna) | 2040 | 2190 | 19.269414 | 93 |
hepatitis c treatment | 1340 | 1389 | 19.269399 | 96 |
locally advanced cervical cancer | 1776 | 1893 | 19.269264 | 94 |
abirateron | 2698 | 2904 | 19.269240 | 93 |
cancer-associated fibroblasts (cafs) | 2137 | 2298 | 19.269100 | 93 |
classical hodgkin lymphoma | 1397 | 1456 | 19.269062 | 96 |
abiraterone | 2693 | 2899 | 19.269052 | 93 |
anti-cancer therapy | 2897 | 3113 | 19.268970 | 93 |
nodal staging | 1487 | 1561 | 19.268927 | 95 |
obesity weight loss | 1621 | 1716 | 19.268901 | 94 |
art adherence | 1877 | 2008 | 19.268733 | 93 |
bcr-abl1 | 2068 | 2222 | 19.268697 | 93 |
sustained viral response | 1389 | 1447 | 19.268623 | 96 |
organ-confined | 2189 | 2356 | 19.268582 | 93 |
secondary stroke | 1534 | 1616 | 19.268392 | 95 |
middle east respiratory syndrome coronavirus | 1970 | 2113 | 19.268368 | 93 |
maternal obesity | 3507 | 3734 | 19.268324 | 94 |
pcnsl | 2024 | 2174 | 19.267837 | 93 |
pancreatic cancer (pc) | 2768 | 2980 | 19.267776 | 93 |
hcv replication | 2215 | 2386 | 19.267469 | 93 |
hormone-refractory | 1945 | 2086 | 19.267436 | 93 |
acute ischaemic stroke | 2399 | 2587 | 19.267284 | 93 |
denv infection | 1611 | 1706 | 19.267279 | 94 |
hiv-related stigma | 1245 | 1279 | 19.267030 | 97 |
glucagon-like peptide-1 receptor agonist | 2250 | 2425 | 19.267015 | 93 |
virological failure | 2122 | 2284 | 19.266968 | 93 |
obesity and overweight | 2239 | 2413 | 19.266964 | 93 |
opioid use disorder (oud) | 2102 | 2262 | 19.266825 | 93 |
biochemical recurrence (bcr) | 1392 | 1452 | 19.266774 | 96 |
diabetes diagnosis | 2402 | 2591 | 19.266732 | 93 |
chronic kidney disease patients | 2922 | 3143 | 19.266485 | 93 |
advanced non-small-cell lung cancer | 3155 | 3383 | 19.266458 | 93 |
reproductive healthcare | 2036 | 2189 | 19.266457 | 93 |
art initiation | 3886 | 4110 | 19.266033 | 95 |
upper tract urothelial | 1655 | 1758 | 19.265860 | 94 |
advanced non-small-cell lung cancer (nsclc) | 1563 | 1652 | 19.265703 | 95 |
lifetime cancer risk | 2036 | 2190 | 19.265602 | 93 |
human neuroblastoma sh-sy5y | 1512 | 1593 | 19.265534 | 95 |
neoadjuvant setting | 1707 | 1818 | 19.265531 | 94 |
non-muscle-invasive bladder cancer | 1396 | 1458 | 19.265145 | 96 |
cancer susceptibility gene | 2277 | 2457 | 19.265140 | 93 |
oncolytic viruses | 2342 | 2528 | 19.265125 | 93 |
cancer drug discovery | 1643 | 1745 | 19.265017 | 94 |
pediatric asthma | 2471 | 2668 | 19.264959 | 93 |
cancer mouse model | 1466 | 1540 | 19.264906 | 95 |
mucosa-associated lymphoid tissue (malt) lymphoma | 1442 | 1512 | 19.264899 | 95 |
folfox | 3929 | 4154 | 19.264849 | 95 |
non-muscle invasive | 1808 | 1934 | 19.264814 | 93 |
programmed cell death ligand | 1953 | 2098 | 19.264755 | 93 |
anticancer treatments | 1545 | 1632 | 19.264753 | 95 |
ln metastases | 1495 | 1574 | 19.264653 | 95 |
urothelial carcinoma (uc) | 1285 | 1328 | 19.264557 | 97 |
breast cancer therapy | 3186 | 3418 | 19.264513 | 93 |
non-small cell lung cancer cells | 2041 | 2197 | 19.264392 | 93 |
risk of obesity | 4165 | 4381 | 19.264331 | 95 |
co-infected patients | 1899 | 2038 | 19.263995 | 93 |
progression-free and overall survival | 2429 | 2624 | 19.263980 | 93 |
internal tandem duplication | 1509 | 1591 | 19.263838 | 95 |
cancer quality of life | 4378 | 4583 | 19.263799 | 96 |
enzalutamide | 2570 | 2776 | 19.263778 | 93 |
hepatitis c patients | 3287 | 3522 | 19.263699 | 93 |
antiretroviral regimen | 2237 | 2415 | 19.263680 | 93 |
hallmark of cancer | 2658 | 2870 | 19.263661 | 93 |
ascvd | 2642 | 2853 | 19.263653 | 93 |
chronic kidney disease patient | 3079 | 3310 | 19.263632 | 93 |
cvd mortality | 2738 | 2955 | 19.263484 | 93 |
thrombolysis in cerebral infarction | 1220 | 1252 | 19.263448 | 97 |
prostate cancer radiotherapy | 1686 | 1796 | 19.263409 | 94 |
preoperative chemoradiotherapy | 1646 | 1750 | 19.263398 | 94 |
enzalutamid | 2573 | 2780 | 19.263233 | 93 |
adolescent obesity | 1566 | 1658 | 19.262924 | 94 |
trastuzumab. | 2298 | 2483 | 19.262830 | 93 |
latent tb | 2374 | 2566 | 19.262760 | 93 |
response to neoadjuvant chemotherapy | 1974 | 2124 | 19.262634 | 93 |
orthotopic xenograft | 1835 | 1967 | 19.262618 | 93 |
hba 1c | 2136 | 2305 | 19.262476 | 93 |
hmlh1 | 1734 | 1852 | 19.262444 | 94 |
anticancer compound | 2425 | 2622 | 19.262287 | 92 |
cancer outcomes | 4361 | 4571 | 19.262068 | 95 |
direct-acting antiviral agent | 1352 | 1409 | 19.261829 | 96 |
pre-diabetes | 2457 | 2658 | 19.261298 | 92 |
atezolizumab | 2286 | 2472 | 19.261193 | 92 |
obesity paradox | 1349 | 1406 | 19.261154 | 96 |
cancer targeted therapy | 1309 | 1359 | 19.260978 | 96 |
international study of asthma and allergies in childhood | 1136 | 1154 | 19.260953 | 98 |
obesity and type 2 diabetes | 4355 | 4568 | 19.260909 | 95 |
p[8] | 1247 | 1286 | 19.260601 | 97 |
epidermal growth factor receptor-2 | 1584 | 1681 | 19.260588 | 94 |
receptor tyrosine kinase inhibitors | 1565 | 1659 | 19.260551 | 94 |
anti-cancer activities | 1783 | 1910 | 19.260504 | 93 |
cancer cost | 1707 | 1823 | 19.260483 | 94 |
shiga toxin-producing | 3235 | 3475 | 19.260476 | 93 |
sentinel lymph nodes | 3535 | 3777 | 19.260348 | 94 |
overweight or obesity | 4053 | 4283 | 19.260236 | 95 |
allergy asthma | 2789 | 3014 | 19.260111 | 93 |
b16f10 melanoma | 1829 | 1963 | 19.259960 | 93 |
braf inhibitor | 2376 | 2572 | 19.259931 | 92 |
nnrtis | 2108 | 2277 | 19.259931 | 93 |
post-stroke patient | 1800 | 1930 | 19.259925 | 93 |
linkage to care | 1636 | 1742 | 19.259692 | 94 |
circumferential resection margin | 1243 | 1282 | 19.259579 | 97 |
stroke, myocardial infarction | 2158 | 2333 | 19.259548 | 92 |
t790m mutation | 1421 | 1492 | 19.259401 | 95 |
chronic hiv | 1718 | 1837 | 19.259108 | 94 |
hnscc cells | 1295 | 1344 | 19.258952 | 96 |
five-year overall survival | 1963 | 2116 | 19.258786 | 93 |
integrase inhibitors | 1547 | 1640 | 19.258440 | 94 |
sh-sy5y neuroblastoma cell | 1754 | 1879 | 19.258399 | 93 |
peginterferon | 2739 | 2964 | 19.258312 | 92 |
tobacco dependence | 2162 | 2339 | 19.258286 | 92 |
breast cancer mcf-7 cells | 1392 | 1459 | 19.258119 | 95 |
stroke care | 3830 | 4072 | 19.258059 | 94 |
a/h1n1 | 1933 | 2083 | 19.258040 | 93 |
neoplasm staging | 1751 | 1876 | 19.257970 | 93 |
cancer targeting | 1496 | 1581 | 19.257947 | 95 |
post-stroke patients | 1744 | 1868 | 19.257947 | 93 |
breast cancer stem cells | 1587 | 1687 | 19.257857 | 94 |
brca1 brca2 | 1893 | 2038 | 19.257807 | 93 |
microvascular invasion | 1676 | 1790 | 19.257774 | 94 |
non-hodgkin lymphoma (nhl) | 3521 | 3768 | 19.257761 | 93 |
xenograft tumor model | 2249 | 2436 | 19.257606 | 92 |
hcc progression | 2374 | 2573 | 19.257583 | 92 |
head-and-neck cancer | 1322 | 1377 | 19.257507 | 96 |
uncomplicated malaria | 1936 | 2087 | 19.257494 | 93 |
obesity prevalence | 3755 | 4000 | 19.257412 | 94 |
prostate cancer (cap) | 1192 | 1223 | 19.257401 | 97 |
interstitial lung disease (ild) | 3967 | 4207 | 19.257058 | 94 |
cancer chemopreventive | 2202 | 2385 | 19.256925 | 92 |
hiv diagnosis | 3946 | 4187 | 19.256917 | 94 |
human cervical cancer cell | 1771 | 1900 | 19.256902 | 93 |
checkpoint inhibition | 2408 | 2611 | 19.256865 | 92 |
prostate cancer cell lines | 4391 | 4611 | 19.256862 | 95 |
cancer immunity | 2200 | 2383 | 19.256757 | 92 |
subtypes of breast cancer | 1763 | 1891 | 19.256745 | 93 |
basal-like | 3248 | 3495 | 19.256670 | 93 |
nonsmall cell | 3557 | 3806 | 19.256640 | 93 |
advanced hepatocellular carcinoma | 3407 | 3656 | 19.256613 | 93 |
colorectal cancer cell line | 3021 | 3262 | 19.256608 | 93 |
cancer pain relief | 2134 | 2310 | 19.256592 | 92 |
chronic hepatitis c virus infection | 1928 | 2079 | 19.256564 | 93 |
dengue virus (denv) | 3791 | 4037 | 19.256547 | 94 |
breast cancer surgery | 3014 | 3255 | 19.256457 | 93 |
denv-2 | 1453 | 1532 | 19.256433 | 95 |
a(h1n1) | 2707 | 2933 | 19.256401 | 92 |
advanced chronic kidney disease | 1470 | 1552 | 19.256330 | 95 |
h7n9 | 1948 | 2102 | 19.256208 | 93 |
cancer disparities | 1366 | 1430 | 19.256120 | 96 |
cancer drug resistance | 2374 | 2575 | 19.256106 | 92 |
human epidermal growth factor receptor-2 | 1534 | 1627 | 19.256060 | 94 |
stroke risk factors | 2101 | 2274 | 19.255971 | 92 |
hereditary breast cancer | 1533 | 1626 | 19.255875 | 94 |
human neuroblastoma sh-sy5y cell | 1404 | 1475 | 19.255800 | 95 |
stroke centers | 1239 | 1280 | 19.255770 | 97 |
cancer metabolism | 2934 | 3173 | 19.255733 | 92 |
non-melanoma skin cancer | 3314 | 3564 | 19.255579 | 93 |
seasonal influenza vaccine | 1555 | 1652 | 19.255465 | 94 |
influenza a (h1n1) | 2581 | 2800 | 19.255387 | 92 |
lymphovascular space | 1253 | 1297 | 19.255245 | 97 |
cancer burden | 2759 | 2990 | 19.255180 | 92 |
kras mutations | 3534 | 3786 | 19.255126 | 93 |
suicide ideation | 3419 | 3671 | 19.255039 | 93 |
stroke outcome | 4034 | 4276 | 19.254978 | 94 |
stroke risk factor | 2447 | 2656 | 19.254962 | 92 |
tumor cell apoptosis | 2559 | 2777 | 19.254951 | 92 |
extrathyroidal extension | 1383 | 1451 | 19.254914 | 95 |
epidermal growth factor receptor mutation | 1332 | 1391 | 19.254680 | 96 |
and cancer therapy | 1838 | 1979 | 19.254559 | 93 |
tb diagnosis | 2112 | 2288 | 19.254547 | 92 |
usual interstitial pneumonia | 1795 | 1930 | 19.254458 | 93 |
cancer registry data | 2404 | 2610 | 19.254421 | 92 |
human prostate cancer cell line | 1844 | 1986 | 19.254408 | 93 |
hev infection | 2074 | 2246 | 19.254174 | 92 |
human hepatocellular carcinoma cell | 2518 | 2734 | 19.254139 | 92 |
hereditary breast and ovarian cancer | 1436 | 1514 | 19.254125 | 95 |
methicillin-resistant s. aureus (mrsa) | 2854 | 3092 | 19.254021 | 92 |
clinicopathologic factors | 2744 | 2976 | 19.253961 | 92 |
prostate cancer screening | 2566 | 2786 | 19.253938 | 92 |
chronic kidney disease epidemiology collaboration | 1269 | 1317 | 19.253867 | 96 |
antiretroviral medication | 1626 | 1736 | 19.253831 | 94 |
symptomatic intracranial hemorrhage | 1576 | 1678 | 19.253760 | 94 |
endovascular thrombectomy | 1521 | 1614 | 19.253627 | 94 |
melanoma progression | 2050 | 2220 | 19.253432 | 92 |
programmed death-ligand 1 | 3125 | 3375 | 19.253311 | 93 |
panitumumab | 1885 | 2034 | 19.253174 | 93 |
early-stage breast cancer | 4366 | 4596 | 19.253143 | 95 |
carcinoma hepatocellular | 3284 | 3538 | 19.253118 | 93 |
programmed cell death protein 1 | 2475 | 2689 | 19.253080 | 92 |
papillary thyroid carcinoma (ptc) | 4280 | 4515 | 19.253058 | 95 |
cancer gene expression | 2266 | 2461 | 19.252765 | 92 |
type 1 and type 2 diabetes | 3937 | 4187 | 19.252762 | 94 |
oscc cells | 1676 | 1795 | 19.252657 | 93 |
hiv rna level | 1253 | 1299 | 19.252503 | 96 |
diabetes prevention program | 1361 | 1427 | 19.252474 | 95 |
incident cvd | 1279 | 1330 | 19.252343 | 96 |
immunosuppressive tumor microenvironment | 1526 | 1621 | 19.252326 | 94 |
long-acting reversible | 1635 | 1748 | 19.252186 | 94 |
advanced rectal cancer | 4136 | 4380 | 19.252135 | 94 |
epidermal growth factor receptor tyrosine kinase inhibitor | 1579 | 1683 | 19.252123 | 94 |
overall and disease-free survival | 2582 | 2806 | 19.252020 | 92 |
mother-to-child transmission of hiv | 1615 | 1725 | 19.251970 | 94 |
rectal cancer surgery | 3571 | 3829 | 19.251945 | 93 |
progression-free survival rate | 2133 | 2315 | 19.251621 | 92 |
5-year dfs | 1594 | 1701 | 19.251536 | 94 |
cancer phenotype | 2080 | 2256 | 19.251439 | 92 |
nk/t-cell | 1356 | 1422 | 19.251329 | 95 |
ncdb | 1636 | 1750 | 19.251307 | 93 |
asthma children | 2839 | 3081 | 19.251024 | 92 |
neoadjuvant chemotherapy. | 3491 | 3751 | 19.250942 | 93 |
multikinase inhibitor | 1763 | 1897 | 19.250903 | 93 |
human hepatocellular carcinoma (hcc) | 1940 | 2099 | 19.250845 | 92 |
pre-exposure prophylaxis (prep) | 3114 | 3368 | 19.250803 | 92 |
sy5y neuroblastoma | 2008 | 2176 | 19.250696 | 92 |
human colorectal cancer cells | 1402 | 1477 | 19.250485 | 95 |
svr12 | 1266 | 1316 | 19.250397 | 96 |
anti-obesity effects | 1341 | 1405 | 19.250382 | 95 |
stroke treatment | 4192 | 4438 | 19.250083 | 94 |
treatment-experienced | 1730 | 1860 | 19.249953 | 93 |
ns5a | 2740 | 2978 | 19.249918 | 92 |
spoligotyping | 1490 | 1581 | 19.249896 | 94 |
avian influenza viruses | 2965 | 3215 | 19.249868 | 92 |
cancer drug development | 1776 | 1913 | 19.249868 | 93 |
clinicopathologic factor | 2787 | 3028 | 19.249815 | 92 |
cancer microenvironment | 1696 | 1821 | 19.249722 | 93 |
liver cancer cells | 3187 | 3445 | 19.249707 | 93 |
influenza a(h1n1) | 1664 | 1784 | 19.249702 | 93 |
carcinoma, hepatocellular | 1216 | 1257 | 19.249654 | 97 |
diabetes type 1 | 1863 | 2013 | 19.249460 | 93 |
recurrence-free survival rate | 1958 | 2121 | 19.249418 | 92 |
mtb/rif | 1950 | 2112 | 19.249366 | 92 |
total lesion glycolysis | 1380 | 1452 | 19.249290 | 95 |
time to progression (ttp) | 1655 | 1774 | 19.249261 | 93 |
neoadjuvant chemotherapy (nact) | 1374 | 1445 | 19.249176 | 95 |
tyrosine kinase inhibitors (tki) | 1379 | 1451 | 19.249065 | 95 |
crizotinib | 2813 | 3057 | 19.248861 | 92 |
breast cancer subtype | 3833 | 4094 | 19.248762 | 94 |
artemisinin-based combination | 1754 | 1889 | 19.248616 | 93 |
cancer immunotherapies | 1719 | 1849 | 19.248281 | 93 |
prior stroke | 1581 | 1689 | 19.248155 | 94 |
colorectal cancer cell lines | 2008 | 2179 | 19.248122 | 92 |
obesity management | 1617 | 1731 | 19.248082 | 93 |
head and neck squamous cell carcinomas | 2209 | 2404 | 19.248067 | 92 |
programmed death ligand 1 | 2054 | 2231 | 19.247954 | 92 |
disease-free and overall survival | 2629 | 2863 | 19.247605 | 92 |
severe stroke | 1821 | 1967 | 19.247591 | 93 |
metastasectomy | 2667 | 2904 | 19.247414 | 92 |
gemcitabine (gem) | 1471 | 1561 | 19.247229 | 94 |
gleason scores | 1744 | 1879 | 19.247131 | 93 |
malt lymphoma | 3444 | 3711 | 19.247122 | 93 |
cancer resection | 3670 | 3937 | 19.247024 | 93 |
zikv infection | 2110 | 2295 | 19.246978 | 92 |
anaplastic lymphoma kinase | 4883 | 5090 | 19.246926 | 96 |
xenograft tumor growth | 1498 | 1593 | 19.246912 | 94 |
acute stroke treatment | 1211 | 1253 | 19.246873 | 97 |
air pollution exposure | 3266 | 3531 | 19.246825 | 92 |
thyroid cancer cell | 2004 | 2176 | 19.246822 | 92 |
hiv risk behavior | 1987 | 2157 | 19.246639 | 92 |
hcc cell lines | 3974 | 4236 | 19.246543 | 94 |
concurrent chemoradiotherapy (ccrt) | 1357 | 1427 | 19.246521 | 95 |
egfr tyrosine kinase | 3755 | 4022 | 19.246515 | 93 |
highly pathogenic avian influenza virus | 1335 | 1401 | 19.246407 | 95 |
community-acquired pneumonia (cap) | 4523 | 4759 | 19.246342 | 95 |
xenograft tumors | 3833 | 4099 | 19.246332 | 94 |
obesity-related disease | 1324 | 1388 | 19.246331 | 95 |
incident type 2 diabetes | 1168 | 1202 | 19.246265 | 97 |
antitumor immune responses | 2525 | 2753 | 19.246172 | 92 |
current asthma | 1935 | 2099 | 19.245813 | 92 |
anti-her2 | 3273 | 3540 | 19.245798 | 92 |
hmlh | 1787 | 1930 | 19.245677 | 93 |
non-small cell lung cancer patients | 3486 | 3756 | 19.245677 | 93 |
egfr-tki | 4187 | 4443 | 19.245664 | 94 |
treatment of chronic hepatitis c | 2064 | 2245 | 19.245646 | 92 |
insulin glargine | 2371 | 2586 | 19.245590 | 92 |
melanoma differentiation | 1326 | 1391 | 19.245527 | 95 |
nonmelanoma skin cancer | 2666 | 2906 | 19.245383 | 92 |
sexual health. | 1846 | 1998 | 19.245372 | 92 |
oral cancer cell | 1675 | 1801 | 19.245354 | 93 |
non-melanoma skin | 3462 | 3733 | 19.245074 | 93 |
pi-rads | 1394 | 1472 | 19.245051 | 95 |
kshv | 3359 | 3629 | 19.245003 | 93 |
cancer intervention | 1557 | 1664 | 19.244852 | 94 |
tumor-initiating cell | 1482 | 1576 | 19.244849 | 94 |
advanced melanoma | 3135 | 3400 | 19.244843 | 92 |
lung cancer screening | 3580 | 3852 | 19.244724 | 93 |
post stroke | 2388 | 2606 | 19.244591 | 92 |
insulin glargin | 2388 | 2606 | 19.244591 | 92 |
serous ovarian cancer | 2471 | 2697 | 19.244334 | 92 |
hepatocellular carcinoma (hcc) cells | 1353 | 1424 | 19.244326 | 95 |
cervical cancer prevention | 1784 | 1928 | 19.244289 | 93 |
lung cancer a549 | 1440 | 1527 | 19.244279 | 94 |
asthma care | 1959 | 2128 | 19.244271 | 92 |
pathological complete response | 3901 | 4170 | 19.244159 | 94 |
tumor necrosis factor-related | 2976 | 3236 | 19.244141 | 92 |
in vitro anticancer | 2835 | 3088 | 19.243988 | 92 |
bxpc-3 | 1642 | 1764 | 19.243983 | 93 |
stroke rehabilitation. | 1735 | 1872 | 19.243806 | 93 |
lung cancer screen | 3595 | 3869 | 19.243685 | 93 |
cervical cancer (cc) | 2013 | 2190 | 19.243541 | 92 |
r-chop | 2623 | 2863 | 19.243283 | 92 |
nk/t-cell lymphoma | 1290 | 1350 | 19.243132 | 96 |
breast cancer development | 2763 | 3013 | 19.243128 | 92 |
cancer apoptosis | 1440 | 1528 | 19.243097 | 94 |
esophageal cancer (ec) | 1679 | 1808 | 19.242955 | 93 |
ribavirin (rbv) | 1467 | 1560 | 19.242927 | 94 |
ovarian cancer risk | 1814 | 1964 | 19.242857 | 92 |
pc3 cells | 2551 | 2786 | 19.242819 | 92 |
clear cell renal cell carcinoma (ccrcc) | 2992 | 3255 | 19.242778 | 92 |
recurrent pregnancy loss | 2852 | 3108 | 19.242719 | 92 |
chronic kidney diseases | 2255 | 2462 | 19.242655 | 92 |
her2+ | 3398 | 3673 | 19.242603 | 93 |
metastatic progression | 2499 | 2730 | 19.242544 | 92 |
oncolytic adenovirus | 1393 | 1473 | 19.242382 | 95 |
scchn | 1700 | 1833 | 19.242311 | 93 |
common toxicity criteria | 1509 | 1610 | 19.242294 | 94 |
direct-acting antivirals (daas) | 1225 | 1273 | 19.242288 | 96 |
children with obesity | 1376 | 1453 | 19.242191 | 95 |
cardiovascular diseases (cvds) | 3620 | 3897 | 19.242122 | 93 |
colorectal carcinoma (crc) | 1716 | 1852 | 19.241852 | 93 |
programmed death-ligand | 3256 | 3530 | 19.241701 | 92 |
stage i nsclc | 1177 | 1216 | 19.241566 | 97 |
mda-mb-468 | 2033 | 2215 | 19.241501 | 92 |
anaplastic large cell lymphoma | 3111 | 3381 | 19.241492 | 92 |
a549 lung cancer cells | 1237 | 1288 | 19.241396 | 96 |
first-line setting | 1252 | 1306 | 19.241310 | 96 |
egfr inhibitors | 2730 | 2981 | 19.241090 | 92 |
human lung cancer cells | 2475 | 2706 | 19.241055 | 91 |
metastasis-free survival | 4469 | 4721 | 19.240968 | 95 |
risk of type 2 diabetes | 4860 | 5084 | 19.240909 | 96 |
h1n1 pandemic | 1457 | 1550 | 19.240836 | 94 |
platinum-resistant | 1553 | 1663 | 19.240818 | 93 |
anaplastic thyroid cancer | 1338 | 1409 | 19.240750 | 95 |
suicide idea | 3578 | 3858 | 19.240620 | 93 |
associated cancers | 1886 | 2049 | 19.240568 | 92 |
uterine cervical neoplasm | 1720 | 1858 | 19.240497 | 93 |
tongue squamous cell carcinoma | 1688 | 1821 | 19.240376 | 93 |
secondary stroke prevention | 1289 | 1351 | 19.240234 | 95 |
stroke management | 1656 | 1784 | 19.240158 | 93 |
microsatellite stable | 1325 | 1394 | 19.240140 | 95 |
brca mutations | 1330 | 1400 | 19.240083 | 95 |
risk of cardiovascular diseases | 2782 | 3038 | 19.240074 | 92 |
acute stroke patients | 3762 | 4042 | 19.240062 | 93 |
hiv-1-infected patients | 2749 | 3003 | 19.239978 | 92 |
gleason grade | 2434 | 2663 | 19.239798 | 91 |
stable coronary artery disease (cad) | 1156 | 1192 | 19.239784 | 97 |
cancer predisposition | 3818 | 4098 | 19.239667 | 93 |
diabetes and cardiovascular disease | 3748 | 4029 | 19.239652 | 93 |
complicated malaria | 2202 | 2407 | 19.239607 | 91 |
transcatheter arterial chemoembolization | 2923 | 3188 | 19.239555 | 92 |
recurrent miscarriage | 2903 | 3167 | 19.239518 | 92 |
alcohol use disorders identification test (audit) | 1165 | 1203 | 19.239511 | 97 |
cardioembolic stroke | 2045 | 2231 | 19.239443 | 92 |
primary central nervous system lymphoma | 2377 | 2601 | 19.239427 | 91 |
obesity epidemic | 4619 | 4865 | 19.239425 | 95 |
obesity treatment | 3689 | 3971 | 19.239425 | 93 |
clinicopathologic parameter | 2365 | 2588 | 19.239281 | 91 |
tumor xenograft model | 1952 | 2126 | 19.239053 | 92 |
cancer experience | 2683 | 2934 | 19.238944 | 91 |
epithelial–mesenchymal transition (emt) | 2321 | 2540 | 19.238900 | 91 |
influenza a virus (iav) | 2219 | 2427 | 19.238785 | 91 |
osimertinib | 2001 | 2182 | 19.238767 | 92 |
mouse xenograft model | 3816 | 4098 | 19.238712 | 93 |
biliary tract cancer | 2251 | 2463 | 19.238479 | 91 |
metastasis prognosis | 1938 | 2111 | 19.238219 | 92 |
cancer cell migration and invasion | 1428 | 1518 | 19.238127 | 94 |
cancer stem cell marker | 1390 | 1473 | 19.238034 | 94 |
stroke event | 2009 | 2192 | 19.237973 | 92 |
brca1 and brca2 mutation | 1275 | 1336 | 19.237940 | 95 |
ovarian cancer (oc) | 2648 | 2898 | 19.237884 | 91 |
pathways in cancer | 2023 | 2208 | 19.237856 | 92 |
response evaluation criteria | 4544 | 4799 | 19.237729 | 95 |
clinicopathologic parameters | 2344 | 2567 | 19.237705 | 91 |
breast cancer gene | 3096 | 3372 | 19.237701 | 92 |
people with cancer | 1843 | 2003 | 19.237555 | 92 |
type 1 dm | 1420 | 1509 | 19.237553 | 94 |
glucagon-like peptide-1 receptor agonists | 1435 | 1527 | 19.237289 | 94 |
anti-tb drug | 2282 | 2499 | 19.237270 | 91 |
her2-overexpressing | 1202 | 1249 | 19.237268 | 96 |
entecavir | 2965 | 3236 | 19.237223 | 92 |
oncogenic driver | 2327 | 2549 | 19.237133 | 91 |
hormone-refractory prostate cancer | 1277 | 1339 | 19.237130 | 95 |
molecular targeted therapy | 2355 | 2580 | 19.237065 | 91 |
aggressive cancer | 3635 | 3922 | 19.237037 | 93 |
progression of ckd | 1723 | 1865 | 19.237016 | 92 |
exposure to air pollution | 2630 | 2880 | 19.236960 | 91 |
lenvatinib | 1710 | 1850 | 19.236926 | 92 |
arsenic exposure | 3410 | 3696 | 19.236817 | 92 |
micrometastasis | 2679 | 2933 | 19.236784 | 91 |
cervical cancer cell line | 2421 | 2653 | 19.236759 | 91 |
cancer cell invasion | 3471 | 3758 | 19.236692 | 92 |
egfr-mutated | 1316 | 1386 | 19.236621 | 95 |
rectal cancer treatment | 1448 | 1543 | 19.236579 | 94 |
cancer network | 5074 | 5290 | 19.236572 | 96 |
baseline cd4 | 2080 | 2274 | 19.236536 | 91 |
multidrug-resistant tuberculosis | 3496 | 3784 | 19.236292 | 92 |
chronic hepatitis c infection | 1518 | 1626 | 19.236229 | 93 |
advanced pancreatic cancer | 3287 | 3572 | 19.236047 | 92 |
hereditary nonpolyposis colorectal cancer | 1680 | 1816 | 19.236031 | 93 |
direct-acting antiviral agents | 1232 | 1286 | 19.235886 | 96 |
esophageal cancer cell | 1791 | 1945 | 19.235772 | 92 |
axillary lymph node dissection (alnd) | 1354 | 1432 | 19.235769 | 95 |
asthma quality of life | 1201 | 1249 | 19.235563 | 96 |
raf inhibitor | 2969 | 3243 | 19.235544 | 92 |
low rectal cancer | 1783 | 1936 | 19.235542 | 92 |
pulmonary tuberculosis (ptb) | 1689 | 1827 | 19.235507 | 92 |
diffuse large b-cell lymphomas | 1290 | 1356 | 19.235216 | 95 |
breast cancer recurrence | 2036 | 2226 | 19.235092 | 91 |
hiv drug resistance | 1468 | 1568 | 19.235038 | 94 |
asthma medication | 2570 | 2818 | 19.235019 | 91 |
human hepatocellular carcinoma cells | 1457 | 1555 | 19.235012 | 94 |
anti-cancer treatment | 1997 | 2182 | 19.234880 | 92 |
brca2 gene | 2049 | 2241 | 19.234856 | 91 |
ductal carcinoma in situ (dcis) | 4081 | 4365 | 19.234759 | 93 |
malignant cancer | 2791 | 3056 | 19.234740 | 91 |
coronary artery calcium | 3358 | 3647 | 19.234728 | 92 |
adjuvant chemoradiotherapy | 4370 | 4642 | 19.234722 | 94 |
cancer population | 3202 | 3487 | 19.234713 | 92 |
drug-resistant cancer | 1308 | 1378 | 19.234603 | 95 |
middle east respiratory syndrome coronavirus (mers-cov) | 1428 | 1521 | 19.234564 | 94 |
molecular-targeted | 1713 | 1856 | 19.234431 | 92 |
brafv600e | 2418 | 2653 | 19.234396 | 91 |
colorectal cancer surgery | 1676 | 1813 | 19.234351 | 92 |
cardiovascular disease prevention | 2204 | 2416 | 19.234314 | 91 |
detectable viral load | 1934 | 2111 | 19.234192 | 92 |
antiretroviral (arv) | 1657 | 1791 | 19.234177 | 93 |
substance use disorder treatment | 1157 | 1197 | 19.234175 | 97 |
melanoma treatment | 1581 | 1702 | 19.234172 | 93 |
targeted cancer | 4614 | 4873 | 19.234157 | 95 |
coronary artery calcium (cac) | 1480 | 1583 | 19.234116 | 93 |
obesity intervention | 1191 | 1238 | 19.234100 | 96 |
diffuse large b cell lymphoma (dlbcl) | 1357 | 1437 | 19.233988 | 94 |
chronic kidney disease stage | 1300 | 1369 | 19.233862 | 95 |
anticancer compounds | 1679 | 1817 | 19.233844 | 92 |
micropapillary | 1924 | 2100 | 19.233811 | 92 |
substance use disorders (sud) | 1185 | 1231 | 19.233781 | 96 |
hiv incidence | 3276 | 3565 | 19.233694 | 92 |
anti-cancer therapies | 1658 | 1793 | 19.233327 | 92 |
triple negative breast cancer (tnbc) | 2235 | 2452 | 19.233240 | 91 |
hiv cohort | 1246 | 1305 | 19.232876 | 95 |
tb drugs | 2385 | 2619 | 19.232731 | 91 |
clinical benefit rate | 1321 | 1395 | 19.232728 | 95 |
chemical failure | 2186 | 2398 | 19.232636 | 91 |
human neuroblastoma sh-sy5y cells | 1250 | 1310 | 19.232608 | 95 |
hereditary nonpolyposis | 2105 | 2307 | 19.232600 | 91 |
hepatitis c virus (hcv) genotype | 1235 | 1292 | 19.232581 | 96 |
cancer cell migration | 4564 | 4830 | 19.232578 | 94 |
du145 cell | 1887 | 2059 | 19.232563 | 92 |
plasma viral load | 2298 | 2523 | 19.232560 | 91 |
mcf-7 breast cancer cells | 3920 | 4213 | 19.232539 | 93 |
early stage breast cancer | 2111 | 2314 | 19.232409 | 91 |
sustained virological response | 5486 | 5670 | 19.232404 | 97 |
urinary bladder neoplasm | 1852 | 2019 | 19.232351 | 92 |
latent tb infection | 1571 | 1692 | 19.232288 | 93 |
coronary computed tomography angiography | 2707 | 2970 | 19.232269 | 91 |
tumor progression and metastasis | 2215 | 2431 | 19.232209 | 91 |
suicide gene therapy | 1112 | 1144 | 19.232202 | 97 |
brafv600 | 2718 | 2982 | 19.232146 | 91 |
cancer specific survival | 1476 | 1580 | 19.232130 | 93 |
high hiv prevalence | 1433 | 1529 | 19.232123 | 94 |
vascular disease prevention | 2329 | 2558 | 19.232092 | 91 |
cardiovascular and cerebrovascular disease | 2002 | 2191 | 19.232048 | 91 |
hcv coinfection | 1169 | 1213 | 19.231930 | 96 |
raf inhibitors | 1734 | 1883 | 19.231884 | 92 |
non-small cell lung cancer cell | 3006 | 3288 | 19.231877 | 91 |
pc-3 cells | 3826 | 4122 | 19.231862 | 93 |
lung cancer prognosis | 2044 | 2239 | 19.231794 | 91 |
cancer pathway | 1815 | 1977 | 19.231736 | 92 |
stroke units | 1512 | 1623 | 19.231668 | 93 |
experimental stroke | 1690 | 1832 | 19.231658 | 92 |
5-year overall survival rate | 3913 | 4208 | 19.231657 | 93 |
ipilimumab | 4289 | 4572 | 19.231611 | 94 |
oncogenic pathway | 2535 | 2785 | 19.231574 | 91 |
mtct | 3183 | 3473 | 19.231546 | 92 |
human pancreatic cancer cell | 2545 | 2796 | 19.231498 | 91 |
glargine | 2992 | 3274 | 19.231465 | 91 |
concurrent chemotherapy | 3287 | 3581 | 19.231111 | 92 |
anti-pd-l1 | 2411 | 2650 | 19.231025 | 91 |
cutaneous squamous cell carcinoma | 3156 | 3446 | 19.230995 | 92 |
clinicopathological variable | 2681 | 2944 | 19.230993 | 91 |
lung cancer (lc) | 1536 | 1652 | 19.230939 | 93 |
asthma prevalence | 1784 | 1942 | 19.230930 | 92 |
clinicopathological variables | 2641 | 2901 | 19.230897 | 91 |
total mesorectal excision (tme) | 1385 | 1473 | 19.230767 | 94 |
virologic response | 5129 | 5355 | 19.230733 | 96 |
raltegravir | 1880 | 2053 | 19.230720 | 92 |
esophageal cancer patients | 2623 | 2882 | 19.230590 | 91 |
lymph node staging | 1523 | 1637 | 19.230551 | 93 |
cause-specific survival | 2148 | 2358 | 19.230531 | 91 |
uterine cervical neoplasms | 1556 | 1676 | 19.230489 | 93 |
active cancer | 1918 | 2097 | 19.230380 | 91 |
stomach neoplasms | 3733 | 4033 | 19.230356 | 93 |
gynecological cancers | 1706 | 1852 | 19.230318 | 92 |
cancer diagnosis and therapy | 1286 | 1355 | 19.230221 | 95 |
egfr-mutant | 1548 | 1667 | 19.230017 | 93 |
hnscc cell lines | 1206 | 1259 | 19.229936 | 96 |
imaging prostate cancer | 1172 | 1218 | 19.229923 | 96 |
active surveillance (as) | 1143 | 1183 | 19.229883 | 97 |
ear cancer | 1709 | 1856 | 19.229819 | 92 |
hiv intervention | 1386 | 1475 | 19.229782 | 94 |
novel anticancer agent | 1391 | 1481 | 19.229738 | 94 |
advanced/metastatic | 1152 | 1194 | 19.229698 | 96 |
clinically significant prostate cancer | 1269 | 1335 | 19.229675 | 95 |
diabetes self-care | 1380 | 1468 | 19.229587 | 94 |
palliative chemotherapy | 3115 | 3406 | 19.229505 | 91 |
egfr-tk | 4411 | 4693 | 19.229493 | 94 |
human cervical cancer | 3138 | 3430 | 19.229465 | 91 |
immunogenic cell death | 2279 | 2506 | 19.229455 | 91 |
vemurafenib | 2227 | 2448 | 19.229436 | 91 |
du145 cells | 1706 | 1853 | 19.229325 | 92 |
sh-sy5y neuroblastoma cells | 1506 | 1618 | 19.229320 | 93 |
plhiv | 2322 | 2554 | 19.229303 | 91 |
immune-related adverse events (iraes) | 1646 | 1783 | 19.229189 | 92 |
driver distraction | 1566 | 1689 | 19.229176 | 93 |
microsatellite instability (msi) | 4088 | 4384 | 19.229165 | 93 |
du-145 | 2103 | 2309 | 19.229137 | 91 |
obesity in children | 3257 | 3554 | 19.228990 | 92 |
circulating tumor dna | 3421 | 3722 | 19.228949 | 92 |
glargin | 3024 | 3312 | 19.228861 | 91 |
hiv services | 1615 | 1747 | 19.228809 | 92 |
immune-related adverse events | 3861 | 4163 | 19.228744 | 93 |
definitive chemoradiotherapy | 1144 | 1185 | 19.228705 | 97 |
urinary bladder neoplasms | 1726 | 1877 | 19.228645 | 92 |
anti-hev | 1481 | 1589 | 19.228617 | 93 |
opioid dependence | 3436 | 3738 | 19.228557 | 92 |
breast cancer metastasis | 3890 | 4192 | 19.228530 | 93 |
receptor tyrosine kinase inhibitor | 3200 | 3496 | 19.228512 | 92 |
locoregional control | 3226 | 3523 | 19.228447 | 92 |
significant cancer | 1385 | 1475 | 19.228326 | 94 |
afatinib | 1830 | 1998 | 19.228317 | 92 |
lymph node metastasis (lnm) | 1742 | 1896 | 19.228281 | 92 |
latent tuberculosis | 4648 | 4919 | 19.228262 | 94 |
chronic hepatitis b (chb) | 4943 | 5192 | 19.228251 | 95 |
resistant tb | 3275 | 3574 | 19.228185 | 92 |
cancer mechanisms | 1318 | 1395 | 19.228120 | 94 |
gi cancer | 1511 | 1625 | 19.228110 | 93 |
cancer symptom | 1745 | 1900 | 19.227786 | 92 |
asthma severity | 3465 | 3769 | 19.227746 | 92 |
cancer cell viability | 1429 | 1528 | 19.227686 | 94 |
cancer prevention and treatment | 1429 | 1528 | 19.227686 | 94 |
breslow thickness | 1498 | 1610 | 19.227662 | 93 |
direct acting antiviral | 1471 | 1578 | 19.227624 | 93 |
adult cancer | 3813 | 4118 | 19.227591 | 93 |
incident cancer | 1585 | 1713 | 19.227448 | 93 |
metastatic pancreatic cancer | 1568 | 1693 | 19.227407 | 93 |
nrtis | 3423 | 3727 | 19.227382 | 92 |
resectable pancreatic cancer | 1895 | 2074 | 19.227343 | 91 |
pazopanib | 1977 | 2168 | 19.227337 | 91 |
cancer aggressiveness | 1417 | 1514 | 19.227333 | 94 |
paclitaxel and carboplatin | 1221 | 1279 | 19.227257 | 95 |
castration resistant | 1365 | 1452 | 19.227220 | 94 |
advanced ckd | 1501 | 1614 | 19.227162 | 93 |
diagnosis of prostate cancer | 2850 | 3131 | 19.227139 | 91 |
muscle invasive | 3887 | 4192 | 19.227126 | 93 |
oncogenic pathways | 2054 | 2256 | 19.227083 | 91 |
oncogenic signaling | 2529 | 2785 | 19.227080 | 91 |
substance dependence | 3063 | 3356 | 19.227031 | 91 |
5-year disease-free survival | 2770 | 3046 | 19.226872 | 91 |
influenza-like illness (ili) | 1298 | 1372 | 19.226825 | 95 |
Download
If you want to run the full query on Scopus.com, simply click the button below. The query will be stored in your clipboard, and you can then paste it in Scopus Advanced Search.